Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference53 articles.
1. Korchagina D, Vataire A, Toumi M, Falissard B, Aballea S. Determinants of orphan drug prices in France: a regression analysis. Orphanet J Rare Dis. 2017;12(1):75–90.
2. Cohen JP, Felix A. Are payers treating orphan drugs differently? J Mark Access Health Policy. 2014;2(1):1–5.
3. Commission European. Regulation (EC) no. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Union. 2000;L 18:1–9.
4. Orofino J, Soto J, Casado MA, Oyaguez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy. 2010;8(5):301–15.
5. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7(1):74–81.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献